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We have found that 26 of 54 (48%) untreated patients 
with leprosy had serum migration inhibitory activity, 
and that this was present in tuberculoid, borderline, and 
lepromatous forms of the disease. Patients with active 
recreational states; i.e., reversal reactions, Lucio's re-
action, or erythema nodosum leprosum, were particu-
larly apt to have this inhibitory activity. The prevalence 
of inhibitory activity did not vary significantly with 
treatment, dinitrochlorobenzene responsiveness, tuber-
culin responsiveness, or serum lysozyme levels. 
Leprosy and sarcoidosis have several similarities. Clinically, 
it is widely recognized that each may mimic the other a nd each 
must be differentiated from the other [1]. Histopathologically, 
some of' the granulomatous expressions of leprosy are similar 
to, and often impossible to distinguish from, those of sarcoidosis 
[2]. Biochemically, both diseases manifest elevated serum levels 
of lysozyme [3,4] and angiotensin-converting enzyme [5,6]. Im-
munologically, both have hyperimmunoglobulinemia and both 
have a variable umesponsiveness to intradermal antigens or 
epicutaneous haptens [7,8]. 
Recently, in. a study of patients with sarcoidosis, migration 
inhibitory activity was found in their sera [9]. The inhibitory 
activity had th e physical ch aracteristics of migration inhibition 
factor (MIF), and its presence was associated with cutaneous 
anergy. These findings prompted us to seek migration inhibitory 
activity in the sera of patients with leprosy. 
In previous studies of inhibitory activity in leprosy, Katz et 
al (10] and Han et al (ll] found that lymphocytes from lep-
romatous subjects failed to, or only weakly, elaborated MIF 
when stimulated in vitro with Mycobacterium leprae, but lym-
phocytes from tuberculoid individuals produced large amounts 
of MIF. Sher et al [12] found that polymorphonuclear leuko-
cytes from lepromatous subjects had abnormal movements to 
a greater degree than did those from tuberculoid patients. S her 
et al [12] and Ward et al [13] demonstrated abnormal chemo-
taxis of polymorphs when incubated with sera from leproma-
tous subjects. Ward et al [13] presented evidence that their 
findings were due to the presence of a factor that inactivates 
chemotactic factors such as C3 and C5 chemotactic fragments . 
Godal et al (14] found that sera from lepromatous subjects 
produced no llihibition in the leukocyte migration inhibition 
test. We have sought for evidence ofrnigration inhibitory activ-
ity in the serum. Migration inhibitory activity was found to be 
present in the sera of patients with leprosy, a nd this activity 
was strongly associated with clinically active reactional states. 
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MATERIALS AND METHODS 
Patients 
Serum samples were obtained from 10::1 patients at the Los Angeles 
County-University of Southern California Medical Center and 5 h"om 
the United States Public Health Service Clinic, San Pedro, Cali fornia . 
The samples were frozen at -20°C for up to 3 years un til studied. The 
diagnosis of leprosy was established by conventional clinical and his-
tologic criteria, and patients were classified according to R idley's system 
[15). For analysis, patients were placed into a tuberculoid category 
(Ridley's polar tuberculoid and borderline with tuberculoid features 
groups), a borderline category (Ridley's borderline and borderline with 
lepromatous features groups), or a lepromatous category (Ridley'S 
subpolar and polar lepromatous groups). 
Three reactional states were recognized. Reversal reactions [16], 
occulTing in borderline and tubercu loid subjects, were found in both 
treated and untreated patients. Erythema nodosum leprosum (ENL) 
[17] was restricted to lepromatous subjects but was seen in both treated 
and untreated SUbjects. Lucio's reaction (L8], occurring only in individ-
uals with diffuse nonnodular lepromatous leprosy, was seen only in 
untreated patients. Tuberculin testing and attempted dinitrochloro-
benzene (DNCB) sensitization were performed as previously described 
[19]. Briefly, a tuberculin test was interpreted as positive if 5 tuberculin 
units of purified protein derivative (PPD) elicited 10 mm or more of 
induration at 48 or 72 hr, and as negative if 4 mm or less. DNCB 
sensitization was in terpreted as positive when, 2-3 weeks after at-
tempted sensitization, a primary fla ir occurred or induration 01' vesic-
ulation was elicited by a challenge dose of 0.1 mg. 
In untreated patients, serum samples were obtained afte r establish-
ing the diagnosis of leprosy, but prior to therapy, attempted DNCB 
sensitization, or tuberculin administration. DNCB challenge and tuber-
culin skin tests were performed 2-3 weeks after attempted sensitization 
with DNCB. 
The patients were of diverse geographic origin: 85 from Mexico, 6 
each from Vietnam and the Philippines, 3 each from Cuba and Poly-
nesia, 2 each from Burma and Thailand, and 1 from Korea. The controls 
consisted of 25 Mexican-born dermatology cl inic patients with banal 
dermatoses who had an age distribution and sex ratio similar to those 
of the 85 Mexican patients. 
In Vitro Macrophage Migration Assay 
Migration inhibitory activity was assayed as previously described 
[9]. Brielly, the areas of migration of guinea pig peritoneal macrophages 
in media containing study 01' control serum were measul'ed and com-
paJ"ed. Two assays consisting of 4 replicate capillal'Y tubes were em-
ployed on each specimen. T lwee serum samples out of 21.4 samples 
were found nonspecifically cytotoxic since the inhibited migration of 
macrophages at 24 hl' had remained inhibited even at 48 and 96 hr 
without showing any reversibility of the migration inhibition. These 
were excluded from analysis of the resu lts. The data were expressed as 
percent inhibition computed according to the following formu la: 
% inhibi tion = 100 
migl'ation area in media containing patient serum 
. . d ' X 100 
migratIOn area 111 me Ia containing normal serum 
For convenience in tabulating data, the results were interpreted as 
negative, or - , if the percent of inhibition ranged from 0-15%; as 
marginal, 01' ±, if 15-25%; as positive, or +, if 25-35%; and as positive, 
or ++, if 35-45%. For statistical analysis (the chi square), - and ± 
results aJ'e taken together as showing no inhibitory activity, and + and 
++ results aJ'e taken together as showing positive inhibitory activity. 
Characterization of Serum Factors 
As previously described [9], physical chemical characterization of 
the substance having inhibitory activity was studied by heating, at-
tempted dialysis, and by Sephadex G-lOO gel filtration. 
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Serum lysozyme was measured by the lysoplate method of Osserman 
a nd Lawlor [4]. 
RESULTS 
Migration Inhibition Activity in Leprosy Patients 
Macrophage migration inhibition assays were performed on 
214 serum samples from 108 patients and on 25 samples from 
25 controls. In the 25 controls, some degree of inhibitory activity 
was present in 2 individuals (8%). Among the patients with 
leprosy, the inhibitory activity was present at one time or 
another in 57 of 108 patients; and if the patients had marginal 
activity are included, 76 of 108 patients had shown a positive 
activity. Such prevalence of positive inhibitory activity in lep-
rosy patients was significantly greater (p < 0.001) than in 
controls. 
In untreated patients, 26 of 54 patients (48%) demonstrated 
positive activity and this was also significantly higher (p < 
0.001) than in controls (see Table I) . Also in each major cate-
gory, i.e., tuberculoid, borderline, and lepromatous, a significant 
difference was obtained: p = 0.0053, 0.027, and < 0.01, respec-
tively (see Table I). Each untreated patient was tested only 
once in the untreated state; therefore, the prevalence rate is not 
inflated by multiple tests or multiple samples. 
Association of R eactional States with Inhibitory Activity 
A strong association was found between positive serum inhib-
itory activity and the presence of active reactional states. The 
data concei·ning untreated patients with reactional states are 
summarized in Table I. Of the 13 untreated patients with active 
reactional states, 12 (92%) had positive inhibitory activity, 
which is highly significant with p = 0.0000003 when compared 
with controls. In contrast, of 41 untreated subjects without 
reactional states, only 15 had. positive inhibitory activity-less 
highly significant, p < 0.02, when compared with controls. Also 
when comparing the prevalence of positive inhibitory activity 
among patients with reactional states to those without reac-
tional states, a significant difference was found, p < 0.00l. 
Furthermore, this significant association between positive 
serum inhibitory activity and reactional states persisted when 
t he untreated patients were subdivided according to the type of 
reactional state; i.e., 4/ 4 with reversal reactions, 5/ 5 with Lu-
cio's reaction, and 3/4 with ENL were positive, with p = 0.006, 
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0.001, and 0.01, respectively (see Table I). In contrast, nonreac-
tional tuberculoid, borderline, and lepromatous patients as sep-
arate categories showed only 1 significant departure, p = 0.026, 
0.1, and 0.07, respectively (see Table 11) . 
Finally, the significant association between serum inhibitory 
activity and reactional states was also found in treated patients 
(see Table II) . Thus, 6 of 7 treated patients with active reversal 
reactions and 9 of 14 with active ENL had positive serum 
inhibitory activity: p = 0.0002 and 0.0005, respectively, as com-
pared with controls; and taken collectively, p < 0.001, as com-
pared with controls. Each of these 21 dapsone-treated, reac-
t ional-state untreated, patients was tested only once before 
initiating thalidomide or prednisone therapy; therefore, the 
stated prevalence rates do not reflect multiple samples or 
nlultiple tests. 
TABLE II. Inhibitory activity in the sera of treated patients and 
selected untreated patients 
Inhibitory % p-Value No. of activity + 
Group pa- or compared 
tients + + with con-
- ± + troIs + + 
In reactional state, dapsone 
treated 
Borderline and tuberculoid 7 0 1 2 4 86 = 0.0002 
Lepromatous 
Active ENL 14 2 3 5 4 62 = 0.0005 
Inactive ENL, long-term 10 1 3 6 0 60 
thalidomide 
Influence of dapsone in non-
reactional states 
Tuberculoid 
Untreated 12 3 4 3 2 42 = 0.026 
1-6 months dapsone 10 2 4 2 2 40 
1-3 years dapsone 10 1 6 2 1 30 
Borderline 
Untreated 17 8 4 3 2 29 = 0.1 
1-6 months dapsone 10 3 2 2 3 50 
1-3 years dapsone 10 2 2 3 3 60 
Lepromatous 
Untrea ted 12 3 5 2 2 33 = 0.G7 
5+ yeru-s dapsone 10 4 3 3 0 30 
TABLE I . Inhibitory activity in the sera of controls an.d untreated patients with leprosy 
Group No. of patient.s 
Inhibitory activity p-Value compared % + OJ· ++ 
± + ++ 
with conlrols (I 
Controls 25 21 2 1 8 
Untreated 
All pa tien ts 54 14 14 14 12 48 < 0.002 
All tuberculoid 14 3 4 4 3 50 = 0.0053 
All borderline 19 8 4 4 3 37 = 0.027 
All leproma tOllS 21 3 6 6 6 57 < 0.01 
No reaction 41 13 13 8 7 37 < 0.02 
In reaction 13 0 1 6 6 92 = 0.0000003 
Bcrderline and tuberculoid 
No reaction 29 11 8 6 4 38 < 0.05 
In reaction 4 0 0 2 2 100 = 0.006 
Lepromatous 
No reaction 12 3 5 2 2 33 = 0.07 
In reaction 9 0 1 4 4 89 = 0.00002 
Lucio 's 5 0 0 2 3 100 = 0.0001 
ENL 4 0 1 2 1 75 = 0.01 
CM!" Responses 
DNCB 
Positive 12 3 0 3 6 75 
Negative 18 3 7 3 5 45 
Tuberculin 
Positive 12 2 2 3 5 67 
Negative 11 2 3 3 3 55 
" < computed with Yates' correction; = computed with Fisher's exact method. 
b Cell-mediated immune. 
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Influence of Dapsone Therapy on Migration Inhib itory 
Activity 
Insuffic ient sera prevented large-scale serial evaluation of the 
effects of dapsone therapy upon serum inhibitory activity. 
However, groups of untreated patient~ not in re.action ~ould be 
compru'ed with groups of treated patients not . J~ reactlO.n (see 
Table Il). Among tuberculoid subjects no difference In the 
distribution of inhibitory activity accompanied 1-6 months or 
1-3 years of therapy. Similarly, the distribution of inhibitory 
activity in lepromatous patients not in reaction was not influ-
enced by 5 or more years of dapsone (an influence of therapy of 
less than 5 years' duration could not be studied in nonreactional 
lepromatous subjects because of too few cases). . . 
Among borderline patients our data suggest an Increasmg 
incidence of positive serum inhibitory factor with both short-
term (1-6 months) and long-term (1-3 years) dapsone therapy. 
This apparent increase could be explained as being due to 
random vaJ'iation in sampling or as reflecting subclinical rever-
sal reactions consistent with the recognized instability of the 
group. . 
Among the 5 Lucio patients some serial data were available. 
In these untreated patients, 2 were + and 3 were ++. In the 4 
patients tested, after 3 months of treatment, there was. no 
change in the level of inhibitory activity although the reactIOn 
had remitted in all four. In 3 patients tested after 1 year of 
therapy, 2 were unchanged and 1 had become negative. 
Influence of Prednisone and Thalidomide on Inhibitory 
Activity 
In 4 patients with reversal reactions, serial data were avail-
able (not shown) . Three patients with ++ values prior to 
prednisone had - or ± values within 3 weeks of beginning 
prednisone (40 mg per day). The fourth maintained a + value 
for 6 weeks. With lower doses of prednisone, levels of activity 
rose . T hus, large-dose prednisone therapy may be associated 
with some fall in serum inhibitory activity. 
No consistent effect could be observed in association with 
thalidomide treatment for ENL. In 10 patients, serum samples 
were available, both prior to thalidomide therapy and after the 
thalidomide-induced remissions. In only 1 patient was there a 
decrease of 2 grades; in 4 there was a decrease; in 2, an increase; 
and in the other 3, no change in the level of inhibi tory activity. 
Also, the distribution of activity among 14 patients with active 
ENL did not differ greatly from that of 10 ENL patients with 
prolonged, thalidomide-maintained remission (see Table Il) . 
Serum Inhibitor:)' Activity and Delayed- Type Hypersensitivity 
Responses 
As is summarized in Table I, the distribution of serum inhib-
itory activity was similar among PPD-positive and PPD-nega-
tive individuals, the data being from serum obtained on the day 
of, and immediately prior to, skin testing. 
Among untreated patients who were sensitized to DNCB, 
positive serum inhibitory activity was present in 9 of 12, or 75%; 
but in those who did not respond to DNCB, positive activity 
was present in 8 of 18, or 44% (see Table I). These data were 
from serum obtained on the day of, but prior to, attempting 
DNCB sensitization. Similar results were found with serum 
obtained immediately prior to DNCB challenge. The appal'-
ently high prevalence of DNCB responsiveness among patients 
with positive inhib itory activity is understandable as a conse-
quence of the nearly normal ease of DNCB sensitization among 
patients with reactional states [20]. 
Serum Inhibitory Activit:y and Lysozyme Levels 
Eigh t of 10 untreated patients with elevated serum lysozyme 
levels (2 S.D. 01' greater above the normal mean)· had positive 
serum inhibitory activity. This apparently strong relationship 
may reflect r. large number of individuals with Lucio's reaction 
and reversal reactions among untreated hyperlysozymemic pa-
Vol. 79, No.5 
tients [3], rather than an inherent relationship. between serum 
inhibitory activity and lysozym e levels. This IS support~d b~ 
observations in treated patients, where the prevalence of POSI-
tive inhibitory activity was 50% and 55%, respectively, among 
patients with elevated and normal lysozym e levels (data not 
shown). 
Characterization of Serum Factor 
Serum migration inhibitory activity was not destroyed by 
heating at 56°C for 30 min and was nondialyzable. The molec-
ulru' weight of the factor having inhibitory activity was 
10,000-30,000. 
DISCUSSION 
Migration inhibitory activity was present in the sera of pa-
tients with leprosy. Among the diverse manifestations of lep-
rosy, one clear clinical association emerged from t!lis stu~y. 
Positive serum inhibitory activity was strongly aSSOCiated With 
reactional states, whether ENL, Lucio's reaction, or reversal 
reactions. This association was present in both untreated and 
dapsone-treated subjects. Taking dapsone-untreated and 
-treated patients together, positive inhibitory activity was pru"-
ticulru"ly prevalent in Lucio's reaction and reversal reactions, 5/ 
5 and 10/11, respectively; bu t less so in ENL, 12/18. However 
strong these associations may be, the nature .of the relati~nship. 
of the MIF-like activity to the pathogeneSIs of each kmd of 
reactional state is not known. 
The substance with inhibitory activity in the sera of patients 
with leprosy was similar to that found in the sera of patients 
with sarcoidosis [9] and lymphoproliferative disorders [21] in 
that it was heat stable and nondialyzable, but differed in mo-
lecular weigh t (10,000-30,000 as compared to 45,000) [9,21]. 
However, the molecular weight of in vitro elaborated human 
MIF [22] (25,000) is consistent with a relationship between the 
active substance in leprosy serum and human MIF. These data 
again suggest heterogeneity of human MIF, at least in their 
sizes secondary to polymerization or subunit structures [23, 
24]. 
Clearly, further study is needed in order to know whether 
the leprosy serum inhibitory factor is related to MIF or not .. 
Whatever its relationship to MIF, the results will prove to be of 
great interest. Thus, the sera of patients wi th leprosy contain a 
substance with the biologic property of inhibiting the migration 
of macrophages, hypothetically a property of in vivo impor-
tance. The factor is not a nonspecific cytotoxic substance be-
cause the inhibition observed at 24 hr was reversible, with 
macrophages regaining their normal migration pattern at 48-72 
hr. Furthermore, macrophages incubated with the factor-con-
taining serum retained their viability as well as those incubated 
with normal human serum when tested by the trypan blue 
exclusion test. The factor, because it is heat stable, is probably 
unrelated to the chemotactant inactivator described by Ward 
et al [13], which is heat labile. The factor is not an rutifact of 
storage; negative serum has never been reported to become 
positive when frozen at any temperature for many years; fUl"-
thermore, inhibitory activity, if initially present, usually re-
mains present for years at -20°C. 
Ow, finding of inhibitory activity in lepromatous serum is not 
in conflict with the failUl"e of lepromatous lymphocytes to 
elaborate MIF in vitro. The studies of Katz et al [10] and Han 
et al [11] evidently were performed on patients who had no 
active reactional states, but serum inhibitory activity was par-
ticularly prevalent in patients with active reactional states, who 
might be derepressed or desuppressed [20] or in whom the 
inhibitory activity might be generated in response to a challenge 
other than M. leprae. Similarly, Godal et al did not perform 
the leukocyte migration inhibition test in patients with reac-
tional states [14]. 
The biologic significance of the presence of an MIF-like 
substance in leprosy serum may not necessru'ily be directly 
connected to the effect of the substance on merely the mobility 
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of macrophages. For example, most of the substances with t he 
MIF activity reported previously have been shown to have 
various stimulatory activities on macrophages. Thus, it has 
b een difficult to separate MIF activity from macrophage acti-
vating factor (MAF), indicating a possibility that MIF and 
MAF may represent the same molecule [25]. Although we have 
not tested whether the leprosy serum with MIF activity also 
has MAF activi ty, it is most likely from the above considera-
tions that t he leprosy serum with MIF activity may have 
various effects on macrophage functions in addition to their 
mobility. In this context, some of the results from studies on 
d esensitization of delayed hypersensitivity in guinea pigs [26] 
may well be indicative of the biologic significance of MIF 
activity in serum. We have found that macrophages in guinea 
pigs with circulating MIF become activated and shed a factor 
t hat suppresses the production of lymphokines by antigen-
stimulated lymphocytes [26]. It is conceivable, therefore, that 
some of the leprosy patients may also have such a suppressive 
factor elaborated from macrophages activated by t he circulat-
ing substance with MIF activity. In fact, in our preliminary 
study we could detect a suppressor factor in the sera of leprosy 
patients. This serum could inhibit the production of MIF by 
a ntigen-stimulated guinea pig lymphocytes. Further studies on 
this point ar e now in progress to reveal the rela tionship between 
such a suppressive factor and an MIF-like substance. In any 
event, the presence of a substance t hat affects at least one 
function of macrophages may have a more profound significance 
in th e pathogenesis of various clinical stages of leprosy than its 
effect on macrophage mobility. 
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